Autologous and allogeneic mesenchymal stem cells in organ transplantation: What do we know about their safety and efficacy?

Current Opinion in Organ Transplantation

Volumn 19, Issue 1, 2014, Pages 65-72

  Alagesan, Senthilkumar ^a   Griffin, Matthew D ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

clinical trials; immune tolerance; inflammation; mesenchymal stem cells; organ transplantation

Indexed keywords

EID: 84895903158     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000043     Document Type: Review

References (47)

1. .Tan J, Wu W, Xu X, et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA 2012; 307:1169-1177.
2. Reinders ME, de Fijter JW, Roelofs H, et al. Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study. Stem Cells Transl Med 2013; 2:107-111.
3. Franquesa M, Hoogduijn MJ, Reinders ME, et al. Mesenchymal stem cells in solid organ transplantation (MiSOT) fourth meeting: lessons learned from first clinical trials. Transplantation 2013; 96:234-238.
4. Perico N, Casiraghi F, Introna M, et al. Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol 2011; 6:412-422.
5. Peng Y, Ke M, Xu L, et al. Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. Transplantation 2013; 95:161-168.
6. Griffin MD, Elliman SJ, Cahill E, et al. Adult mesenchymal stromal cell therapy for inflammatory diseases: how well are we joining the dots? Stem Cells 2013; 31:2033-2041
7. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371:1579-1586.
8. Duijvestein M, Vos ACW, Roelofs H, et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut 2010; 59:1662-1669.
9. Hare JM, Traverse JH, Henry TD, et al. A randomized, double-blind, placebocontrolled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 2009; 54:2277-2286.
10. Eggenhofer E, Benseler V, Kroemer A, et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol 2012; 3:297.
11. .Nystedt J, Anderson H, Tikkanen J, et al. Cell surface structures influence lung clearance rate of systemically infused mesenchymal stromal cells. Stem Cells 2013; 31:317-326.
12. Moll G, Rasmusson-Duprez I, von Bahr L, et al. Are therapeutic human mesenchymal stromal cells compatible with human blood? Stem Cells 2012; 30:1565-1574.
13. Casiraghi F, Azzollini N, Todeschini M, et al. Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation. Am J Transplant 2012; 12:2373-2383.
14. Ren G, Zhao X, Wang Y, et al. CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFa. Cell Stem Cell 2012; 11:812-824.
15. Schu S, Nosov M, O'Flynn L, et al. Immunogenicity of allogeneic mesenchymal stem cells. J Cell Mol Med 2012; 16:2094-2103.
16. Griffin MD, Ryan AE, Alagesan S, et al. Antidonor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far? Immunol Cell Biol 2013; 91:40-51.
17. .Seifert M, Stolk M, Polenz D, Volk HD. Detrimental effects of rat mesenchymal stromal cell pretreatment in a model of acute kidney rejection. Front Immunol 2012; 3:202.
18. Huang XP, Sun Z, Miyagi Y, et al. Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation 2010; 122:2419-2429.
19. Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol 2012; 12:383-396.
20. Oh JY, Lee RH, Yu JM, et al. Intravenous mesenchymal stem cells prevented rejection of allogeneic corneal transplants by aborting the early inflammatory response. Mol Ther 2012; 20:2143-2152.
21. Casiraghi F, Azzollini N, Cassis P, et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol 2008; 181:3933-3946.
22. .Eggenhofer E, Popp FC,Mendicino M, et al. Heart grafts tolerized through thirdparty multipotent adult progenitor cells can be retransplanted to secondary hosts with no immunosuppression. Stem Cells Transl Med 2013; 2:595-606.
23. Eggenhofer E, Renner P, Soeder Y, et al. Features of synergism between mesenchymal stem cells and immunosuppressive drugs in a murine heart transplantation model. Transpl Immunol 2011; 25:141-147.
24. Ge W, Jiang J, Arp J, et al. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation 2010; 90:1312-1320.
25. Ge W, Jiang J, Baroja ML, et al. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am J Transplant 2009; 9:1672-1760.
26. Vaes B, Van 't Hof W, Deans R, Pinxteren J. Application of MultiStem1 allogeneic cells for immunomodulatory therapy: clinical progress and preclinical challenges in prophylaxis for graft versus host disease. Front Immunol 2012; 3:345.
27. Hare JM, Traverse JH, Henry TD, et al. Comparison of allogeneic versus autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the poseidon randomized trial. JAMA 2012; 308:2369-2379.
28. Plock JA, Schnider JT, Schweizer R, Gorantla VS. Are cultured mesenchymal stromal cells an option for immunomodulation in transplantation? Front Immunol 2013; 4:41.
29. Hall SR, Tsoyi K, Ith B, et al. Mesenchymal stromal cells improve survival during sepsis in the absence of heme oxygenase-1: the importance of neutrophils. Stem Cells 2013; 31:397-407.
30. Mei SH, Haitsma JJ, Dos Santos CC, et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med 2010; 182:1047-1057.
31. Lee Ryang H, Yoon N, Reneau John C, Prockop D J. Preactivation of human MSCs with TNF-A enhances tumor-suppressive activity. Cell Stem Cell 2012; 11:825-835.
32. Mantovani A. MSCs, macrophages, and cancer: a dangerous mé nage-À -trois. Cell Stem Cell 2012; 11:730-732.
33. Dimarino AM, Caplan AI, Bonfield TL. Mesenchymal stem cells in tissue repair. Front Immunol 2013; 4:201.
34. Franquesa M, Herrero E, Torras J, et al. Mesenchymal stem cell therapy prevents interstitial fibrosis and tubular atrophy in a rat kidney allograft model. Stem Cells Dev 2012; 21:3125-3135.
35. Maria Spaggiari G, Moretta L. Cellular and molecular interactions of mesenchymal stem cells in innate immunity. Immunol Cell Biol 2013; 91:27-31.
36. Prockop DJ, Youn Oh J. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol Ther 2012; 20:14-20.
37. McKernan R, McNeish J, Smith D. Pharma's developing interest in stem cells. Cell Stem Cell 2010; 6:517-520.
38. Dander E, Lucchini G, Vinci P, et al. Mesenchymal stromal cells for the treatment of graft-versus-host disease: understanding the in vivo biological effect through patient immune monitoring. Leukemia 2012; 26:1681-1684.
39. Galipeau J. The mesenchymal stromal cells dilemma: does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graftversus- host disease represent a death knell or a bump in the road? Cytotherapy 2013; 15:2-8.
40. Chang JW, Tsai HL, Chen CW, et al. Conditioned mesenchymal stem cells attenuate progression of chronic kidney disease through inhibition of epithelial- to-mesenchymal transition and immune modulation. J Cell Mol Med 2012; 16:2935-2949.
41. Eirin A, Zhu XY, Krier JD, et al. Adipose tissue-derived mesenchymal stem cells improve revascularization outcomes to restore renal function in swine atherosclerotic renal artery stenosis. Stem Cells 2012; 30:1030-1041.
42. Lee MJ, Jung J, Na KH, et al. Antifibrotic effect of chorionic plate-derived mesenchymal stem cells isolated from human placenta in a rat model of CCl(4)-injured liver: potential application to the treatment of hepatic diseases. J Cell Biochem 2010; 111:1453-1463.
43. Toonkel RL, Hare JM, Matthay MA, Glassberg MK. Mesenchymal stem cells and idiopathic pulmonary fibrosis. Potential for clinical testing. Am J Respir Crit Care Med 2013; 188:133-140.
44. Xue J, Li X, Lu Y, et al. Gene-modified mesenchymal stem cells protect against radiation-induced lung injury. Mol Ther 2013; 21:456-465.
45. Qi Y, Jiang D, Sindrilaru A, et al. TSG-6 released from intradermally injected mesenchymal stem cells accelerates wound healing and reduces tissue fibrosis in murine full-thickness skin wounds. J Invest Dermatol 2013; ePub Aug 6.
46. Tzouvelekis A, Paspaliaris V, Koliakos G, et al. A prospective, nonrandomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis. J Transl Med 2013; 11:1479.
47. Reinders ME, Rabelink TJ, de Fijter JW. The role of mesenchymal stromal cells in chronic transplant rejection after solid organ transplantation. Curr Opin Organ Transplant 2013; 18:44-50.